Biohaven Pauses Midstage Study of Seizure Treatment, Impact on Xenon
Biohaven (BHVN) experienced a significant drop in its stock price after announcing the pause of enrollment in a midstage clinical trial for opakalim due to safety concerns. The FDA has mandated that Biohaven evaluate potential human toxicity from a drug metabolite identified during testing. Opakalim is being developed as a treatment for focal onset seizures, but preclinical findings in rats have raised red flags regarding its safety profile. This development could delay regulatory approval and impact the company's timeline for bringing the therapy to market. The news has implications not only for Biohaven’s stock performance but also potentially benefits Xenon Pharmaceuticals (XEN), a competitor with similar therapeutic interests, as investors may shift focus toward alternative seizure treatment options.
Tickers: $BHVN